Actively Recruiting
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects
Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2025-11-17
16
Participants Needed
1
Research Sites
20 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single-dose subcutaneous injection of SHR-3045 in healthy subjects.
CONDITIONS
Official Title
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand trial procedures and possible adverse events and voluntarily participate
- Able to provide written informed consent
- Male or female aged 18 to 55 years
- Males weighing at least 50 kg, or females weighing at least 45 kg
- Body mass index between 19 and 28 kg/m2
- No clinically significant abnormalities in medical history, physical exams, vital signs, or lab tests
You will not qualify if you...
- Participation in other clinical trials with investigational drugs or devices within 3 months before screening
- Known or suspected history of drug abuse
- Addiction to tobacco or alcohol
- Unable to follow dietary requirements during the study
- Any other conditions that may interfere with trial result evaluation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Frist Affiliated Hospital of USTC (Anhui Provincial Hospital)
Hefei, Anhui, China, 230001
Actively Recruiting
Research Team
J
Junlin Huang
CONTACT
Y
Yifan Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here